<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610958</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-05-022</org_study_id>
    <nct_id>NCT03610958</nct_id>
  </id_info>
  <brief_title>Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.</brief_title>
  <official_title>Prospective, Single Center, Open-labeled Single Arm Study, to Asses the Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss in Healthy Over Weight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epitomee medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epitomee medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design to demonstrate the safety and performance of the Epitomee Device
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single center, open-labeled single arm study. The subjects will be enrolled in
      one investigational site. Subjects meeting eligibility criteria will receive multiple capsule
      intakes, 1 capsule twice daily for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">September 4, 2014</start_date>
  <completion_date type="Anticipated">September 4, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single center, open-labeled single arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation of the Device administration.</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Normal Gastroscopic examination as assessed by an independent safety committee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the change in subjects' weight presented as percent total body loss (%TBL)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Subjects loss of weight described as %TBL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Epitomee Device arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.
The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epitomee Device</intervention_name>
    <description>A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.</description>
    <arm_group_label>Epitomee Device arm</arm_group_label>
    <other_name>Tulip Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 21 ≤ Age &lt;65 years

          2. 28 &lt; BMI ≤ 40 kg/m2

          3. Healthy subject

          4. Normal blood count and chemistry

          5. Subject is able and willing to give informed consent

          6. Subject is able and willing to participate in the study and follow protocol procedures

        Exclusion Criteria:

        A. General health and medication

          1. Any history or evidence of significant cardiac, renal, neurologic, pulmonary,
             gastrointestinal, hematologic abnormality, chronic hepatic disease or any other
             disease or symptom which in the judgment of the investigator would interfere with the
             study or confound the results

          2. Symptomatic or unbalanced metabolic syndrome, or, symptomatic or unbalanced type 2
             diabetes - such patients with minor symptoms may be allowed according to the PI
             discretion

          3. Intake of chronic medication which may affect the GI or interrupt with the treatment,
             unless approved by the PI discretion

          4. Taking thyroid hormone deficiency drugs (such as L-thyroxine)

          5. Hemoglobin level under 11 gm/dl

             B. Weight loss history and status

          6. Currently using pharmaceutical agents or food supplements for weight loss

          7. History of weight reduction of more than 5% of total body weight in the past 6 months

          8. Eating disorder such as anorexia, bulimia compulsory overeating or emotional eating*

             C. Specific GI history and status

          9. History or evidence of any active liver disease. (abnormal liver functions: &gt;1.5 times
             upper limit)

         10. Subject with Inflammatory Bowel Disease (IBD)

         11. Significant swallowing disorders

         12. Less than 3 natural bowel movements per week

         13. Past history of any gastrointestinal surgery (excluding uncomplicated appendectomy)

         14. Malabsorption disorders

             D. General

         15. History of food allergy according to PI decision

         16. Female subjects who are breastfeeding or have a positive pregnancy test at screening
             or at any time during the study

         17. History of alcohol or drug abuse within 6 months of screening

         18. Mental disorders

         19. Currently participating in an ongoing clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Shirin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Kamila Gonczarowski Institute of Gastroenterology Assaf Harofeh Medical Center,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcomes measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within six months of study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

